Xontogeny

A diverse pipeline of early-stage life sciences companies

Xontogeny has made a number of seed investments and continues to incubate a pipeline of early-stage life sciences companies across a wide variety of modalities and therapeutic areas. We typically do not communicate about our portfolio companies until they have received Series A financing, however we are happy to discuss our portfolio further if you are interested in collaboration, partnering or investment opportunities in our companies.

portfolio companies include:

bioharmony-portco-final
landos-portco-final
Morphiex
Nephraegis Therapeutics
NephroDI Therapeutics
Peroxitech
Quellis Biosciences
Shifa Biomedical
Tellus Therapeutics